Tigatuzumab

Cat. No.: HY-P99270

CAS No.: 918127-53-4

Target: Apoptosis

Pathway: Apoptosis

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description

Tigatuzumab (CS-1008) is a humanized IgG1 monoclonal antibody targets death receptor 5 (DR5). Tigatuzumab induces cell apoptosis of cancer cells and inhibits tumor growth in vivo. Tigatuzumab can be used for the research of cancer[1].

In Vitro

Tigatuzumab is sensitive to MIA PaCa-2 cells and BxPC-3 cells with IC_{50} values of 2.95 and 8.21 μg/mL, respectively[1].
Tigatuzumab (3-8 μg/mL; 5 h) induces apoptosis of cancer cells[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis[1]

Cell Line:	MIA PaCa-2 and BxPC-3 cell lines
Concentration:	3 and 8 μg/mL
Incubation Time:	5 hours
Result:	Induced cell apoptosis, and the methionine restriction increased the caspase activation and apoptosis in pancreatic cancer cells.

In Vivo

Tigatuzumab (3 mg/kg; i.v. weekly for 4 weeks) effectively represses the tumor growth in human pancreatic cancer MIA PaCa-2-RFP orthotopic mouse model[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Nude mice with MIA PaCa-2-RFP human pancreatic cancer cells injection[1]
Dosage:	3 mg/kg
Administration:	Intravenous injection; 3 mg/kg weekly for 4 weeks
Result:	Reduced the tumor volume and decreased the density of viable cancer cells in tumors.

REFERENCES

[1]. Yamamoto J, et al. Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an

orthotopic mouse model. Cancer Lett. 2020 Nov 1;492:174-184.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA